About
Solutions
Pipeline
Publications
News
Careers
CN
Open main menu
News
Track Our News on
2023-11-23
MindRank has Nominated Kinase Inhibitors as Preclinical Candidates with the Potential to be Best-in-Class for IND-Enabling Studies
2023-11-06
MindRank Founder Zhangming Niu Named to Hurun China Under40s 2023
2023-11-06
MindRank Nominates a Preclinical Candidate with Dual-Target Capabilities for IND-Enabling Studies, the “First-in-Class” in the DDR Area
2023-10-20
MindRank Awarded “Future Unicorn | The Inaugural Dual 30 AI Ranking of Innovative Companies” by KPMG China
2023-10-18
Journal of Biomolecular Structure and Dynamics | The Binding Mechanism of Failed, in Processing and Succeed Inhibitors Target SARS-CoV-2 Main Protease
2023-10-11
Bioinformatics | An Extensive Benchmark Study on Biomedical Text Generation and Mining with ChatGPT
2023-09-07
MindRank Announces the Commencement of Phase IIa Clinical Study of MDR-001 in China
2023-09-01
MindRank Features in Forbes Asia 100 to Watch 2023 List
2023-08-10
MindRank Secures Funding from the Dynamic Resilience Program for its Pan-European Collaborative Project
2023-07-29
ICML 2023 | Rethinking Explaining Graph Neural Networks via Non-parametric Subgraph Matching
2023-07-18
MindRank Secures Over $20 Million in A+ Round Financing, Propelling Innovative Drug Pipeline and AI Platform Commercialization
2023-06-12
MindRank Announces First-in-Human Phase 1 Study of MDR-001 in China
Previous
2 / 5
Next
Previous
2 / 5
Next